Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Ophthalmologic Medicine(Electronic Edition) ›› 2022, Vol. 12 ›› Issue (06): 357-361. doi: 10.3877/cma.j.issn.2095-2007.2022.06.007

• Review • Previous Articles     Next Articles

Research progress of ocular hemangiopericytoma

Yifan Du1, Xiaohui Lyn2, Nan Wang1, Xuan Zhang3, Jinjin Wang1, Mei Sun1, Shan He1, Ningli Wang1, Jianmin Ma1,()   

  1. 1. Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100730, China
    2. Ophthalmology Center, Affiliated Hospital of Weifang Medical University, Weifang 261000, China
    3. Department of Ophthalmology, Tai′an City Central Hospital, Tai′an 271000, China
  • Received:2021-03-03 Online:2022-12-28 Published:2023-03-02
  • Contact: Jianmin Ma

Abstract:

Hemangiopericytoma (HPC) is a kind of recurrent and malignant vascular tumor originated from pericytes, most of which originate from deep soft tissues of musculoskeletal system, such as lower limbs, pelvis and retroperitoneum, while HPC originated from orbit is rare. In recent years, more and more ocular HPC is found and diagnosed. The clinical manifestations of ocular HPC are complex and changeable, while there is no clear corresponding relationship between the pathological results and the malignant degree of patients. In addition, there are still many controversies in the diagnosis and treatment of ocular HPC. Based on that, the relevant literature about the incidence, clinical characteristics and the diagnosis and treatment methods of ocular HPC are summarized.

Key words: Hemangiopericytoma, Orbit, Diagnosis, Treatment

Copyright © Chinese Journal of Ophthalmologic Medicine(Electronic Edition), All Rights Reserved.
Tel: 0086-10-58269646 E-mail: zhykyxzz@163.com
Powered by Beijing Magtech Co. Ltd